merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>significant safety risks, including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>might discourage patients from participating in trials for treatments that could be better</answer>
<question_number>3</question_number>
<answer>no correlation between the removal of amyloid plaques and the clinical response in individual subjects</answer>
<question_number>4</question_number>
<answer>raises concerns about Kisunla's safety</answer>
<question_number>5</question_number>
<answer>expectation that patients can stop Kisunla after their plaques are cleared</answer>
<question_number>6</question_number>
<answer>might discourage patients from participating in trials for treatments that could be better</answer>
<question_number>7</question_number>
<answer>patients can stop the drug after it clears amyloid, reducing overall cost and inconvenience</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>participants with intermediate tau levels declined more slowly than those with high levels</answer>